The Food and Drug Administration (FDA) confirmed this Tuesday the safety and efficacy of Moderna’s Covid-19 vaccine, in a first analysis prior to its authorization, which indicated that the inoculation of the second vaccine could begin in the United States in the coming days.
The US agency determined that the results of clinical trials and safety data are “consistent with recommendations required by the Guide in the Authorization of Emergency Use for Vaccines to prevent Covid-19 “.
Moderna indicated that in clinical trials it has shown 94.1% efficiency to prevent disease and 100% to avoid serious cases.
“The FDA has determined that the manufacturer has provided adequate information to ensure the quality and consistency of the vaccine for product authorization,” the document added.
This Thursday an independent advisory committee will meet to evaluate the new vaccine, a meeting in which approval is expected and that would give green light to start your US supply in the next few days.
This Monday the first injections of the vaccine developed by Pfizer and BioNTech began in the United States, with what Moderna would be the second serum available to combat covid-19 in the country.
Both Moderna’s vaccine, provisionally christened mRNA-1273, and that of Pfizer and BioNTech, which is for now called BNT162b2, require two doses to protect against coronavirus Sars CoV-2.
One of the most important differences between Moderna’s vaccine and the one already licensed from Pfizer refers to the preservation of the vaccine.
While that of Pfizer has to be kept at a very low temperature – less than 80 Cº-, which requires special freezers that are not accessible to everyone, that of Moderna has the ability to remain stable in temperatures between 2 ° and 8 ° C for a period of 30 days, although for export and long-term storage, the vaccine may be kept at a temperature of 20 degrees below zero for a period of six months.
The Centers for Disease Control and Prevention (CDC) initially recommended vaccinating health workers and those who work or live in facilities dedicated to long-term caresuch as nursing homes or centers for people with disabilities.
In Spain these two groups are joined by the large dependents, groups that will be the first to be vaccinated in our country with the first vaccines to arrive.
The hopeful news of the inoculation of the first vaccines comes amid one of the deadliest streaks since the pandemic began, as the US surpassed the 300,000 deaths confirmed by Covid-19 on Monday.